Two questions may be enough – screening for depression in patients with psoriasis: a multicenter study

Depression is frequently underdiagnosed and insufficiently treated in psoriatic patients in their daily routine. The aim of this study was to screen and analyze the impact of patient and disease characteristics on depression scores.

[1]  L. Azulay-Abulafia,et al.  Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence , 2018, The Journal of dermatology.

[2]  R. von Brachel,et al.  How depressed is “depressed”? A systematic review and diagnostic meta-analysis of optimal cut points for the Beck Depression Inventory revised (BDI-II) , 2018, Quality of Life Research.

[3]  J. Weinman,et al.  To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in hidradenitis suppurativa? , 2018, The British journal of dermatology.

[4]  Finlay,et al.  Dermatologists across Europe underestimate depression and anxiety: results from 3635 dermatological consultations , 2018, The British journal of dermatology.

[5]  A. Armstrong,et al.  Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  S. Feldman,et al.  Psoriasis, Depression, and Inflammatory Overlap: A Review , 2017, American Journal of Clinical Dermatology.

[7]  S. Langan,et al.  Psoriasis and comorbid diseases: Epidemiology. , 2017, Journal of the American Academy of Dermatology.

[8]  A. Pietrzak,et al.  Depressiveness, measured with Beck Depression Inventory, in patients with psoriasis. , 2017, Journal of affective disorders.

[9]  Charles H. Smith,et al.  A cross‐sectional survey of the nature and correlates of sleep disturbance in people with psoriasis , 2017, The British journal of dermatology.

[10]  K. Ezzedine,et al.  DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  K. Reich,et al.  Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3” , 2016, Archives of Dermatological Research.

[12]  S. Robinson,et al.  Clinical characteristics of patients with facial psoriasis in Malaysia , 2016, International journal of dermatology.

[13]  Y. Li,et al.  Risk of depression in women with psoriasis: a cohort study , 2015, The British journal of dermatology.

[14]  A. Burden,et al.  Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register , 2015, The British journal of dermatology.

[15]  A. Menter,et al.  Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. , 2015, Journal of the American Academy of Dermatology.

[16]  Dragan M. Svrakic,et al.  Depression in Type 2 Diabetes Mellitus: Prevalence, Impact, and Treatment , 2015, Drugs.

[17]  A. Kimball,et al.  Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR) , 2014, The British journal of dermatology.

[18]  L. Arends,et al.  The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. , 2014, The Journal of investigative dermatology.

[19]  T. Luger,et al.  German psoriasis registry PsoBest: objectives, methodology and baseline data , 2014, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[20]  R. Herings,et al.  Increased antidepressant drug exposure in psoriasis patients: a longitudinal population-based cohort study. , 2013, Acta dermato-venereologica.

[21]  W. Koenig,et al.  Recommendations for detection of individual risk for comorbidities in patients with psoriasis , 2013, Archives of Dermatological Research.

[22]  David J. Margolis,et al.  Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom , 2011, The Journal of investigative dermatology.

[23]  K. Smarr,et al.  Measures of depression and depressive symptoms: Beck Depression Inventory‐II (BDI‐II), Center for Epidemiologic Studies Depression Scale (CES‐D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire‐9 (PHQ‐9) , 2011, Arthritis care & research.

[24]  Jiali Han,et al.  Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study , 2011, The Journal of investigative dermatology.

[25]  E. Park,et al.  Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life. , 2010, Annals of dermatology.

[26]  F. Schneider,et al.  Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. , 2010, Deutsches Arzteblatt international.

[27]  C. Griffiths,et al.  Definition of treatment goals for moderate to severe psoriasis: a European consensus , 2010, Archives of Dermatological Research.

[28]  Andrea B Troxel,et al.  The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. , 2010, Archives of dermatology.

[29]  H. Knopf,et al.  Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis , 2008, The British journal of dermatology.

[30]  F Keller,et al.  [Reliability and validity of the Revised Beck Depression Inventory (BDI-II). Results from German samples]. , 2007, Der Nervenarzt.

[31]  M. Hautzinger,et al.  Reliabilität und Validität des revidierten Beck-Depressions-inventars (BDI-II). Befunde aus deutschsprachigen Stichproben , 2007 .

[32]  Y. Lecrubier.  Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. , 2007, The Journal of clinical psychiatry.

[33]  David J Margolis,et al.  Determinants of quality of life in patients with psoriasis: a study from the US population. , 2004, Journal of the American Academy of Dermatology.

[34]  M. Sprangers,et al.  The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. , 2002, Archives of dermatology.

[35]  Wolzt,et al.  World Medical Association Declaration of Helsinki , 2000, International Journal of Pharmaceutical Medicine.

[36]  J. Weinman,et al.  Patients’ illness perceptions and coping as predictors of functional status in psoriasis: a 1‐year follow‐up , 2000, The British journal of dermatology.

[37]  D M Reboussin,et al.  Psoriasis causes as much disability as other major medical diseases. , 1999, Journal of the American Academy of Dermatology.

[38]  D. Kivlahan,et al.  The AUDIT Alcohol consumption questions (AUDIT-C) : An effective brief screening test for problem drinking , 1998 .

[39]  C. Main,et al.  What patients with psoriasis believe about their condition. , 1998, Journal of the American Academy of Dermatology.

[40]  W. Browner,et al.  Case-finding instruments for depression , 1997, Journal of General Internal Medicine.

[41]  B. Strober,et al.  Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR) , 2018, Journal of the American Academy of Dermatology.

[42]  K. Martires,et al.  Psoriasis and the Risk of Depression in the US Population: National Health and Nutrition Examination Survey 2009-2012. , 2016, JAMA dermatology.

[43]  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[44]  D. Kivlahan,et al.  The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. , 1998, Archives of internal medicine.